Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Baxter
McKesson
Dow
Colorcon

Last Updated: February 3, 2023

CLINICAL TRIALS PROFILE FOR DALIRESP


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Daliresp

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01433666 ↗ Roflumilast and Cognition Completed ZonMw: The Netherlands Organisation for Health Research and Development Phase 2 2011-09-01 The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.
NCT01433666 ↗ Roflumilast and Cognition Completed Maastricht University Medical Center Phase 2 2011-09-01 The aim of the current project is to validate PDE4 inhibitors as a target for cognition enhancers (proof-of-concept) using a translational behaviour-EEG approach. The project will demonstrate whether memory, but also attention, information processing or executive function improves with the PDE4 inhibitor roflumilast in healthy humans.
NCT01443845 ↗ Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Completed AstraZeneca Phase 4 2011-09-30 To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
NCT01443845 ↗ Roflumilast in Chronic Obstructive Pulmonary Disease (COPD) Patients Treated With Fixed Dose Combinations of Long-acting β2-agonist (LABA) and Inhaled Corticosteroid (ICS) Completed Forest Laboratories Phase 4 2011-09-30 To demonstrate the additional benefit of roflumilast when added on to fixed-dose combination (FDC) LABA/ICS in the reduction of exacerbations in subjects with severe to very severe COPD.
NCT01572948 ↗ A Placebo-controlled Trial of Daliresp on Chronic Obstructive Pulmonary Disease (COPD) Completed University of Alabama at Birmingham N/A 2012-06-01 The purpose of the study is to propose that roflumilast is associated with meaningful reductions in biomarkers of pulmonary inflammation and sputum neutrophilia, including confirmation of previously described results, and correlate these findings with improvement in pulmonary function, sputum scores, and quality of life in stable moderate to severe COPD. The investigators aim to demonstrate this regardless of concomitant medication use, including inhaled corticosteroids. Additionally, the investigators hope to provide a mechanistic pathway by which these effects occur.
NCT01745848 ↗ Roflumilast on Markers of Bone Metabolism and Endothelial Function in COPD Completed University of Pittsburgh Phase 4 2013-02-01 Our primary hypothesis is that Roflumilast (500 μcg, once daily) will significantly decrease surrogate markers of bone metabolism and early cardiovascular disease in individuals with moderate to severe airflow obstruction and a chronic bronchitis phenotype.
NCT01765192 ↗ Roflumilast Plus Montelukast in Adults With Severe Asthma Completed AstraZeneca Phase 2 2013-02-01 This study will evaluate the effect of roflumilast 500 μg once daily (QD) plus montelukast 10 mg QD versus 10 mg montelukast QD alone on predose (trough) prebronchodilator forced expiratory volume in the first second (FEV1).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Daliresp

Condition Name

Condition Name for Daliresp
Intervention Trials
COPD 5
Asthma 3
Chronic Obstructive Pulmonary Disease 2
Chronic Bronchitis 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Daliresp
Intervention Trials
Pulmonary Disease, Chronic Obstructive 6
Lung Diseases, Obstructive 5
Lung Diseases 5
Bronchitis, Chronic 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Daliresp

Trials by Country

Trials by Country for Daliresp
Location Trials
United States 78
Canada 5
Argentina 5
Mexico 3
Serbia 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Daliresp
Location Trials
California 4
Alabama 4
Pennsylvania 4
Texas 4
Maryland 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Daliresp

Clinical Trial Phase

Clinical Trial Phase for Daliresp
Clinical Trial Phase Trials
Phase 4 4
Phase 3 3
Phase 2 3
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Daliresp
Clinical Trial Phase Trials
Completed 11
Recruiting 3
Unknown status 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Daliresp

Sponsor Name

Sponsor Name for Daliresp
Sponsor Trials
Johns Hopkins University 3
Forest Laboratories 3
University of Pittsburgh 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Daliresp
Sponsor Trials
Other 22
Industry 7
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Boehringer Ingelheim
Moodys
Dow
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.